Conduit Total Cash From Financing Activities from 2010 to 2025

CDTTW Stock   0.01  0.0001  0.89%   
Conduit Pharmaceuticals Total Cash From Financing Activities yearly trend continues to be fairly stable with very little volatility. Total Cash From Financing Activities is likely to outpace its year average in 2025. During the period from 2010 to 2025, Conduit Pharmaceuticals Total Cash From Financing Activities regression line of quarterly data had mean square error of 1768.3 T and geometric mean of  3,683,246. View All Fundamentals
 
Total Cash From Financing Activities  
First Reported
2010-12-31
Previous Quarter
-143.7 M
Current Value
-136.5 M
Quarterly Volatility
48.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Conduit Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Conduit Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 143.6 K, Selling General Administrative of 4.1 M or Total Revenue of 2.6 B, as well as many indicators such as Price To Sales Ratio of 0.088, Dividend Yield of 0.0235 or PTB Ratio of 0.23. Conduit financial statements analysis is a perfect complement when working with Conduit Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Conduit Pharmaceuticals Correlation against competitors.
For more information on how to buy Conduit Stock please use our How to Invest in Conduit Pharmaceuticals guide.

Latest Conduit Pharmaceuticals' Total Cash From Financing Activities Growth Pattern

Below is the plot of the Total Cash From Financing Activities of Conduit Pharmaceuticals over the last few years. It is Conduit Pharmaceuticals' Total Cash From Financing Activities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Conduit Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Total Cash From Financing Activities10 Years Trend
Slightly volatile
   Total Cash From Financing Activities   
100%
       Timeline  

Conduit Total Cash From Financing Activities Regression Statistics

Arithmetic Mean(15,256,069)
Geometric Mean3,683,246
Coefficient Of Variation(319.96)
Mean Deviation31,217,245
Median1,898,000
Standard Deviation48,812,963
Sample Variance2382.7T
Range154.6M
R-Value(0.55)
Mean Square Error1768.3T
R-Squared0.31
Significance0.03
Slope(5,684,071)
Total Sum of Squares35740.6T

Conduit Total Cash From Financing Activities History

2025-136.5 M
2024-143.7 M
202310.9 M
20222.4 M

About Conduit Pharmaceuticals Financial Statements

Conduit Pharmaceuticals investors use historical fundamental indicators, such as Conduit Pharmaceuticals' Total Cash From Financing Activities, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Conduit Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Cash From Financing Activities-143.7 M-136.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Conduit Stock Analysis

When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
News Freq…Investor S…